Blockchain Registration Transaction Record

Quantum BioPharma's Lucid-MS Set to Revolutionize Multiple Sclerosis Treatment

Quantum BioPharma (NASDAQ: QNTM) advances Lucid-MS, a first-in-class neuroprotective drug for multiple sclerosis, entering Phase 2 trials after promising preclinical results.

This news matters because multiple sclerosis affects millions worldwide, and current treatments only manage symptoms without directly repairing nerve damage. Lucid-MS offers a potential disease-modifying therapy that could halt or reverse disability progression, improving quality of life for patients. Additionally, the novel PET imaging technique could enable earlier diagnosis and better monitoring of treatment efficacy, transforming MS management.